A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug

Adenosine A(2A) receptor antagonists have emerged as an attractive non-dopaminergic target in clinical trials aimed at evaluating improvement in motor deficits in Parkinson's disease (PD). Moreover, preclinical studies suggest that A(2A) receptor antagonists may slow the course of the underlying neurodegeneration of dopaminergic neurons. In this study, we evaluated the efficacy of the new adenosine A(2A) receptor antagonist 8-ethoxy-9-ethyladenine (ANR 94) in parkinsonian models of akinesia and tremor. In addition, induction of the immediate early gene zif-268, and neuroprotective and anti-inflammatory effects of ANR 94 were evaluated. ANR 94 was effective in reversing parkinsonian tremor induced by the administration of tacrine. ANR 94 also counteracted akinesia (stepping test) and sensorimotor deficits (vibrissae-elicited forelimb-placing test), as well as potentiating l-dopa-induced contralateral turning behavior in 6-hydroxydopamine (6-OHDA) lesion model of PD. Potentiation of motor behavior in 6-OHDA-lesioned rats was not associated with increased induction of the immediate early gene zif-268 in the striatum, suggesting that ANR 94 does not induce long-term plastic changes in this structure. Finally, in a subchronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD, ANR 94 protected nigrostriatal dopaminergic neurons from degeneration and counteracted neuroinflammatory processes by contrasting astroglial (glial fibrillary acidic protein, GFAP) and microglial (CD11b) activation. A(2A) receptor antagonism represents a uniquely realistic opportunity for improving PD treatment, since A(2A) receptor antagonists offer substantial symptomatic benefits and possibly disease-modifying activity. The characterization of ANR 94 may represent a further therapeutic opportunity for the treatment of PD with this new class of drugs.

[1]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[2]  M. Hallett,et al.  Levodopa in the treatment of Parkinson's disease: Current controversies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[3]  M. Morelli,et al.  New adenosine A2A receptor antagonists: actions on Parkinson's disease models. , 2005, European journal of pharmacology.

[4]  M. Greenberg,et al.  The regulation and function of c-fos and other immediate early genes in the nervous system , 1990, Neuron.

[5]  P. Jenner,et al.  Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? , 2006, Experimental Neurology.

[6]  T. Schallert,et al.  CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury , 2000, Neuropharmacology.

[7]  M. Morelli,et al.  Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions , 2004, Experimental Neurology.

[8]  J. Wardas.  Neuroprotective role of adenosine in the CNS. , 2002, Polish journal of pharmacology.

[9]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.

[10]  T. Chase,et al.  Translating A2A antagonist KW6002 from animal models to parkinsonian patients , 2003, Neurology.

[11]  A. Pinna.  Novel investigational adenosine A2A receptor antagonists for Parkinson's disease , 2009, Expert opinion on investigational drugs.

[12]  M. Morelli,et al.  Inactivation of neuronal forebrain A2A receptors protects dopaminergic neurons in a mouse model of Parkinson’s disease , 2009, Journal of neurochemistry.

[13]  G. Chiara,et al.  Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated Rats , 1996, The European journal of neuroscience.

[14]  J. Bennett,et al.  Effects of single and multiple treatments with L‐dihydroxyphenylalanine (L‐DOPA) on dopamine receptor–G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions , 1999, Journal of neuroscience research.

[15]  H. Kase,et al.  Adenosine A2a Receptor‐Mediated Modulation of Striatal Acetylcholine Release In Vivo , 1996, Journal of neurochemistry.

[16]  B. Neustadt,et al.  Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression , 2009, Journal of Pharmacology and Experimental Therapeutics.

[17]  E. Vaudano,et al.  KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse , 2005, Neuropharmacology.

[18]  P. Jenner,et al.  Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys , 1998, Annals of neurology.

[19]  A. Björklund,et al.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  M. Andersson,et al.  Striatal fosB Expression Is Causally Linked with l -DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease , 1999, Neurobiology of Disease.

[21]  S. Wachtel,et al.  Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions , 1999, Neuroscience.

[22]  M. Reddington,et al.  Both A1 and A2a Purine Receptors Regulate Striatal Acetylcholine Release , 1990, Journal of neurochemistry.

[23]  K. Fuxe,et al.  Targeting adenosine A2A receptors in Parkinson's disease , 2006, Trends in Neurosciences.

[24]  M. Ochi,et al.  Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. , 2000, European journal of pharmacology.

[25]  P. Jenner,et al.  Combined Use of the Adenosine A2A Antagonist KW-6002 with l -DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys , 2000, Experimental Neurology.

[26]  R. Hauser,et al.  Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[27]  Micaela Morelli,et al.  Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease , 2007, Synapse.

[28]  J. Salamone,et al.  Tremulous Characteristics of the Vacuous Jaw Movements Induced by Pilocarpine and Ventrolateral Striatal Dopamine Depletions , 1997, Pharmacology Biochemistry and Behavior.

[29]  P. Jenner.  Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease , 2005, Expert opinion on investigational drugs.

[30]  Susan H Fox,et al.  Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson’s disease , 2003, Experimental Neurology.

[31]  L. Pellegrino,et al.  stereotaxic atlas of the rat brain , 1967 .

[32]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[33]  J. Salamone,et al.  Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. , 2008, Frontiers in bioscience : a journal and virtual library.

[34]  K. Klotz,et al.  9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[35]  P. Jenner,et al.  The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats , 2007, Brain Research.

[36]  K. Klotz,et al.  Adenosine A2A Receptor Antagonists: New 8‐Substituted 9‐Ethyladenines as Tools for in vivo Rat Models of Parkinson's Disease , 2009, ChemMedChem.

[37]  M. Morelli,et al.  Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated rats , 2002, Synapse.

[38]  M. Umemiya,et al.  A Calcium-Dependent Feedback Mechanism Participates in Shaping Single NMDA Miniature EPSCs , 2001, The Journal of Neuroscience.

[39]  Hiroshi Kase,et al.  Industry forum: Progress in pursuit of therapeutic A2A antagonists , 2003, Neurology.

[40]  E. Hirsch,et al.  Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure , 2004, Glia.

[41]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[42]  T. Chase,et al.  A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease , 2003, Experimental Neurology.

[43]  A. Kelley,et al.  Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity , 2004, Psychopharmacology.

[44]  P. Svenningsson,et al.  Distribution, biochemistry and function of striatal adenosine A2A receptors , 1999, Progress in Neurobiology.

[45]  K. Ikeda,et al.  Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease , 2002, Journal of neurochemistry.

[46]  M. Morelli,et al.  Different responsiveness of striatonigral and striatopallidal neurons to L‐DOPA after a subchronic intermittent L‐DOPA treatment , 2005, The European journal of neuroscience.

[47]  P. Jenner,et al.  The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. , 2006, European journal of pharmacology.

[48]  K. Klotz,et al.  New substituted 9-alkylpurines as adenosine receptor ligands. , 1998, Bioorganic & medicinal chemistry.

[49]  L. Grégoire,et al.  Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys , 1999, Neurology.

[50]  J. Salamone,et al.  Tremulous jaw movements in rats:a model of parkinsonian tremor , 1998, Progress in Neurobiology.